Quantitative repeated open application testing with a rinse-off product in methyldibromo glutaronitrile-sensitive patients: Results of the IVDK

Annice Heratizadeh*, Claudia Killig, Margitta Worm, Stephanie Soost, Dagmar Simon, Andrea Bauer, Vera Mahler, Christian Schuster, Christiane Szliska, Yvonne Frambach, Ricarda Eben, Thomas Werfel, Wolfgang Uter, Axel Schnuch

*Corresponding author for this work
10 Citations (Scopus)

Abstract

Background: While the use of methyldibromo glutaronitrile (MDBGN) in leave-on products is clearly associated with high sensitization or elicitation risk, such a clear-cut relation could be questioned with regard to rinse-off products. Objective: The objective of this study was to find a maximum non-eliciting concentration for rinse-off products in MDBGN patch test-positive patients. Patients and methods: We performed a use-related test [repeated open application test (ROAT)] in patients sensitized to MDBGN with a liquid soap containing three concentrations of MDBGN (50, 200, and 400 p.p.m. MDBGN, respectively). The soap at 50 p.p.m. was used twice daily for 4 weeks. If no reaction of the skin was observed, the product with the next higher concentration was used for another 4 weeks, etc. Results: In total, 32/37 evaluated cases [86.5%; lower exact one-sided 95% confidence limit (CL): 73.7%] did not react to any of the preparations. The remaining reacted as follows: 1/37 reacted to 50 p.p.m., 3/37 to 200 p.p.m., and 1/37 to 400 p.p.m. The cumulative non-response to 50 p.p.m. was 97.3% (lower CL: 87.8%). Conclusions: The majority of subjects sensitized to MDBGN-tolerated rinse-off products containing a maximum concentration of 400 p.p.m. A concentration in rinse-off products in the range of 50 p.p.m. could be regarded as safe for most individuals already sensitized. These concentrations will presumably prevent induction (sensitization) also.

Original languageEnglish
JournalContact Dermatitis
Volume62
Issue number6
Pages (from-to)330-337
Number of pages8
ISSN0105-1873
DOIs
Publication statusPublished - 01.01.2010

DFG Research Classification Scheme

  • 2.22-22 Clinical Immunology and Allergology

Cite this